A phase III, multi-center, 12-month, open-label safety study of SPD465 in adults with attention-deficit hyperactivity disorder (ADHD).
Phase of Trial: Phase III
Latest Information Update: 19 Jan 2017
At a glance
- Drugs Mixed amfetamine salts (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- Sponsors Shire
- 01 Jun 2007 Status change from in progress to completed.
- 30 Sep 2006 New trial record.